Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

How Novo Nordisk’s Wegovy cardiovascular benefits could drive further growth

By Brian Buntz | March 12, 2024

Novo Nordisk logoSemaglutide was already one of the best-selling drugs of recent memory. And Novo Nordisk the fastest-growing Big Pharma firm. Now, the FDA’s decision to expand the label of its weight-loss version of the drug to include cardiovascular benefits could help unlock more growth momentum for Novo Nordisk. This positions Wegovy as the first weight-loss medication also cleared for reducing the risk of heart attack, stroke, or heart-related death in at-risk individuals. The approval, based on a 17,600-patient SELECT study demonstrating a 20% lower risk of cardiac events with Wegovy versus placebo, could have a material impact on sales. The study also found that patients lost an average of 15% of their weight.

The expanded FDA label sanctions the use of Wegovy for reducing the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease who are obese or overweight. This marks a significant breakthrough in public health, offering an effective new treatment option for some of the most prevalent health challenges facing society today.

In the SELECT trial, Wegovy significantly outperformed placebo in reducing major adverse cardiovascular events. Additionally, Wegovy remains an approved treatment for long-term weight management in certain adults and children with obesity or overweight, used alongside a reduced-calorie diet and increased physical activity.

The development has generated significant interest among investors with analysts anticipating this label expansion will significantly impact Novo Nordisk’s sales. Over the past five days, its stock has jumped nearly 9% to $135.11 and 92.27% over the past year.

Recently, the company’s shares surged following the release of preliminary data highlighting Wegovy’s cardiovascular benefits. Potential barriers to adoption, however, include Wegovy’s substantial cost ($1,000 per month in the U.S.), which oculd limit access and reimbursement without legislative changes.

Despite potential cost hurdles, Wegovy’s strong market performance in 2023 ($4.6 billion in sales) and the expanded label, could be a harbinger of future growth.


Filed Under: Metabolic disease/endicrinology
Tagged With: cardiovascular benefits, FDA approval, Novo Nordisk, obesity treatment, SELECT trial, semaglutide, Wegovy
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].

Related Articles Read More >

Shifting GLP-1 research and development: Lessons learned from the first-generation 
Pens to pills: what oral GLP-1s change at the bench
ADA conference roundup: GLP-1 trial results and researchers removed by police
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE